Free Trial
→ Crypto’s crashing…but we’re still profiting (From Crypto Swap Profits) (Ad) Buy OCUL Stock  Free OCUL Stock Alerts

Ocular Therapeutix (OCUL) Financials

Ocular Therapeutix logo
$7.76 -0.14 (-1.77%)
As of 12:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Ocular Therapeutix

Annual Income Statements for Ocular Therapeutix

This table shows Ocular Therapeutix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -29 -40 -45 -63 -60 -86 -156 -6.55 -71 -81 -194
Consolidated Net Income / (Loss)		 -29 -40 -45 -63 -60 -86 -156 -6.55 -71 -81 -194
Net Income / (Loss) Continuing Operations		 -29 -40 -45 -63 -60 -87 -156 -6.55 -71 -81 -194
Total Pre-Tax Income 		-29 -40 -45 -63 -60 -86 -156 -6.55 -71 -81 -194
Total Operating Income		 -27 -38 -43 -62 -59 -86 -63 -78 -79 -82 -172
Total Gross Profit		 0.68 1.43 1.44 1.47 1.53 1.90 15 39 47 53 58
Total Revenue		 0.77 1.75 1.89 1.92 1.99 4.23 17 44 51 58 64
Operating Revenue		 0.77 1.75 1.89 1.92 1.99 4.23 17 44 51 58 64
Total Cost of Revenue		 0.09 0.32 0.44 0.46 0.47 2.33 2.08 4.41 4.54 5.28 5.63
Operating Cost of Revenue		 0.09 0.32 0.44 0.46 0.47 2.33 2.08 4.41 4.54 5.28 5.63
Total Operating Expenses		 28 40 45 63 61 88 78 117 126 136 230
Selling, General & Admin Expense		 6.91 9.17 11 16 19 22 23 32 32 34 61
Marketing Expense		 1.98 3.85 6.70 17 4.94 24 27 35 40 41 42
Research & Development Expense		 19 27 27 31 37 41 29 50 53 61 128
Other Operating Expenses / (Income)		 - - - - - - 0.00 0.00 0.00 0.00 0.00
Total Other Income / (Expense), net		 -1.55 -1.55 -1.38 -1.46 -0.86 -0.57 -93 71 7.62 1.65 -22
Interest Expense		 1.12 1.72 1.68 1.89 1.74 6.10 6.77 6.67 7.02 -2.85 42
Interest & Investment Income		 0.01 0.17 0.30 0.42 0.88 1.23 0.17 0.03 0.80 3.98 20
Other Income / (Expense), net		 -0.44 0.01 -0.00 0.01 - 4.30 -86 78 14 -5.19 -0.48
Other Gains / (Losses), net		 - - - - - -0.57 - - -0.00 -0.00 0.00
Basic Earnings per Share		 ($2.69) ($1.71) ($1.80) ($2.20) ($1.57) ($1.91) ($2.56) ($0.09) ($0.92) ($1.01) ($1.22)
Weighted Average Basic Shares Outstanding		 10.65M 23.24M 24.82M 28.82M 38.12M 45.27M 60.75M 76.39M 76.88M 79.83M 158.27M
Diluted Earnings per Share		 ($2.69) ($1.71) ($1.80) ($2.20) ($1.57) ($1.91) ($2.56) ($0.98) ($0.97) ($1.02) ($1.22)
Weighted Average Diluted Shares Outstanding		 10.65M 23.24M 24.82M 28.82M 38.12M 45.27M 60.75M 82.16M 82.64M 85.60M 158.27M
Weighted Average Basic & Diluted Shares Outstanding		 10.65M 23.24M 24.82M 28.82M 38.12M 45.27M 60.75M 76.75M 77.51M 148.63M 159.02M

Quarterly Income Statements for Ocular Therapeutix

This table shows Ocular Therapeutix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -24 -16 -30 -21 -0.52 -29 -65 -44 -36 -48
Consolidated Net Income / (Loss)		 -24 -16 -30 -21 -0.52 -29 -65 -44 -36 -48
Net Income / (Loss) Continuing Operations		 -24 -16 -30 -21 -0.52 -29 -65 -44 -36 -48
Total Pre-Tax Income 		-24 -16 -30 -21 -0.52 -29 -65 -44 -36 -48
Total Operating Income		 -22 -19 -23 -21 -19 -20 -32 -44 -46 -51
Total Gross Profit		 11 13 12 14 14 13 13 15 14 16
Total Revenue		 12 14 13 15 15 15 15 16 15 17
Operating Revenue		 12 14 13 15 15 15 15 16 15 17
Total Cost of Revenue		 1.07 1.01 1.21 1.30 1.38 1.39 1.33 1.51 1.56 1.23
Operating Cost of Revenue		 1.07 1.01 1.21 1.30 1.38 1.39 1.33 1.51 1.56 1.23
Total Operating Expenses		 32 32 35 34 33 33 45 59 60 66
Selling, General & Admin Expense		 8.53 8.35 9.13 8.21 8.58 8.02 14 20 12 15
Marketing Expense		 10 11 11 11 9.32 9.25 10 9.99 11 11
Research & Development Expense		 14 14 15 15 15 16 21 29 37 41
Total Other Income / (Expense), net		 -2.64 3.82 -7.77 -0.11 19 -9.17 -33 -0.19 9.51 2.19
Interest Expense		 1.80 1.85 1.77 1.99 -11 4.15 32 3.20 3.22 3.11
Interest & Investment Income		 0.29 0.42 0.56 0.75 1.21 1.46 3.92 6.04 5.65 4.67
Other Income / (Expense), net		 -1.13 5.24 -6.56 1.13 6.72 -6.48 -5.15 -3.03 7.08 0.62
Basic Earnings per Share		 ($0.31) ($0.21) ($0.39) ($0.26) ($0.01) ($0.35) ($0.49) ($0.26) ($0.22) ($0.25)
Weighted Average Basic Shares Outstanding		 76.98M 76.88M 77.39M 78.05M 79.37M 79.83M 132.02M 165.82M 166.99M 158.27M
Diluted Earnings per Share		 ($0.31) ($0.19) ($0.39) ($0.26) ($0.25) ($0.12) ($0.49) ($0.26) ($0.22) ($0.25)
Weighted Average Diluted Shares Outstanding		 76.98M 82.64M 77.39M 78.05M 85.14M 85.60M 132.02M 165.82M 166.99M 158.27M
Weighted Average Basic & Diluted Shares Outstanding		 77.01M 77.51M 77.52M 79.38M 79.42M 148.63M 154.89M 155.92M 157.22M 159.02M

Annual Cash Flow Statements for Ocular Therapeutix

This table details how cash moves in and out of Ocular Therapeutix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 20 -6.61 3.65 135 137 -4.48 174 -64 -62 94 196
Net Cash From Operating Activities		 -20 -34 -34 -50 -49 -78 -54 -66 -60 -70 -135
Net Cash From Continuing Operating Activities		 -20 -34 -34 76 71 -78 -54 -66 -60 -70 -135
Net Income / (Loss) Continuing Operations		 -29 -40 -45 63 60 -86 -156 -6.55 -71 -81 -194
Consolidated Net Income / (Loss)		 -29 -40 -45 -63 -60 -86 -156 -6.55 -71 -81 -194
Depreciation Expense		 0.55 0.75 0.88 1.63 2.29 2.53 2.77 2.42 2.11 2.98 3.79
Amortization Expense		 0.13 0.45 0.56 0.43 0.40 3.68 4.42 4.63 4.85 6.11 3.73
Non-Cash Adjustments To Reconcile Net Income		 5.32 4.30 7.19 7.31 7.48 4.35 93 -62 -0.05 10 62
Changes in Operating Assets and Liabilities, net		 2.16 0.50 2.08 3.55 0.59 -1.76 1.49 -3.88 4.52 -8.98 -11
Net Cash From Investing Activities		 -39 -39 37 27 -1.89 -2.24 -0.84 -1.19 -3.72 -6.09 -1.29
Net Cash From Continuing Investing Activities		 -39 -39 37 27 -1.89 -2.24 -0.84 -1.19 -3.72 -6.09 -1.29
Purchase of Property, Plant & Equipment		 -1.26 -1.78 -1.92 -8.25 -1.89 -2.24 -0.84 -1.19 -3.72 -6.09 -1.29
Net Cash From Financing Activities		 79 66 0.59 32 69 75 228 2.85 1.45 170 332
Net Cash From Continuing Financing Activities		 79 66 0.59 32 69 75 228 2.85 1.45 170 332
Repayment of Debt		 -2.51 -2.26 -0.52 -1.89 -5.66 0.00 -3.20 -4.17 0.00 -31 0.00
Issuance of Debt		 15 1.90 0.00 3.70 12 37 0.00 3.72 0.00 82 0.00
Issuance of Common Equity		 70 66 0.91 30 62 38 225 0.99 0.94 118 317
Other Financing Activities, net		 0.04 0.21 0.20 0.69 0.40 0.08 5.79 2.59 0.51 0.55 15
Cash Interest Paid		 0.84 1.25 1.30 1.46 1.52 2.30 2.35 1.93 2.15 5.46 22

Quarterly Cash Flow Statements for Ocular Therapeutix

This table details how cash moves in and out of Ocular Therapeutix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -14 -19 -23 -12 44 85 287 -23 -32 -35
Net Cash From Operating Activities		 -13 -17 -20 -20 -7.73 -22 -34 -25 -37 -39
Net Cash From Continuing Operating Activities		 -13 -17 -20 -20 -7.73 -22 -34 -25 -37 -39
Net Income / (Loss) Continuing Operations		 -24 -16 -30 -21 -0.52 -29 -65 -44 -36 -48
Consolidated Net Income / (Loss)		 -24 -16 -30 -21 -0.52 -29 -65 -44 -36 -48
Depreciation Expense		 0.51 0.49 0.48 0.65 0.89 0.96 0.92 0.96 0.96 0.95
Amortization Expense		 1.23 1.24 1.23 1.25 2.07 1.55 1.97 0.57 0.62 0.58
Non-Cash Adjustments To Reconcile Net Income		 5.59 -4.18 12 3.66 -17 12 41 14 0.58 6.30
Changes in Operating Assets and Liabilities, net		 3.70 1.04 -2.92 -4.95 6.99 -8.10 -13 3.27 -2.23 1.13
Net Cash From Investing Activities		 -0.79 -2.15 -3.38 -1.99 -0.26 -0.46 -0.26 -0.74 -0.09 -0.20
Net Cash From Continuing Investing Activities		 -0.79 -2.15 -3.38 -1.99 -0.26 -0.46 -0.26 -0.74 -0.09 -0.20
Purchase of Property, Plant & Equipment		 -0.79 -2.15 -3.38 -1.99 -0.26 -0.46 -0.26 -0.74 -0.09 -0.20
Net Cash From Financing Activities		 0.37 0.46 0.08 9.65 52 108 321 2.20 4.18 4.51
Net Cash From Continuing Financing Activities		 0.37 0.46 0.08 9.65 52 108 321 2.20 4.18 4.51
Issuance of Common Equity		 - 0.46 0.00 9.24 0.71 108 316 0.49 - 0.52
Other Financing Activities, net		 0.37 - 0.08 0.40 0.06 0.01 4.87 1.70 4.18 3.99
Cash Interest Paid		 0.53 0.63 0.70 0.82 1.34 2.60 13 2.63 2.60 3.34

Annual Balance Sheets for Ocular Therapeutix

This table presents Ocular Therapeutix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 78 110 75 55 73 79 262 205 149 252 458
Total Current Assets		 76 107 70 43 56 60 246 191 130 232 441
Cash & Equivalents		 37 31 33 42 54 54 228 164 102 196 392
Restricted Cash		 - - - - - - - - 0.00 0.15 0.00
Accounts Receivable		 0.33 0.19 0.25 0.23 0.20 2.55 12 21 21 26 32
Inventories, net		 0.13 0.13 0.11 0.12 0.22 0.95 1.20 1.25 1.97 2.31 3.04
Prepaid Expenses		 0.89 1.59 1.39 1.45 1.71 2.23 4.65 4.75 4.03 7.79 13
Plant, Property, & Equipment, net		 1.78 3.10 3.31 10 10 10 8.10 6.96 9.86 12 9.39
Total Noncurrent Assets		 0.23 0.23 1.73 1.61 6.61 8.42 7.61 6.63 9.81 8.09 7.56
Other Noncurrent Operating Assets		 - - - - - 6.66 5.84 4.87 8.04 8.09 7.56
Total Liabilities & Shareholders' Equity		 78 110 75 55 73 79 262 205 149 252 458
Total Liabilities		 19 21 23 29 37 82 186 117 114 161 143
Total Current Liabilities		 5.87 5.38 8.30 13 9.16 12 27 26 31 35 41
Accounts Payable		 1.32 1.96 2.12 3.57 2.97 3.27 2.71 4.59 5.12 4.39 4.18
Accrued Expenses		 3.02 3.38 4.64 4.31 6.19 7.64 14 20 24 29 35
Current Deferred Revenue		 0.19 0.04 - - - - - 0.00 0.58 0.26 0.13
Other Current Liabilities		 - - - - - 1.13 1.36 1.62 1.60 1.59 1.93
Total Noncurrent Liabilities		 14 15 15 16 28 70 159 91 83 126 101
Long-Term Debt		 14 15 14 12 25 49 41 51 54 75 69
Noncurrent Deferred Revenue		 0.11 0.07 0.54 3.39 - 0.00 12 13 13 14 14
Other Noncurrent Operating Liabilities		 - - - - 3.22 21 106 26 15 37 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 59 90 52 26 36 -3.63 76 88 35 91 315
Total Preferred & Common Equity		 59 90 52 26 36 -3.63 76 88 35 91 315
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 59 90 52 26 36 -3.63 76 88 35 91 315
Common Stock		 148 219 226 263 333 380 615 634 652 789 1,206
Retained Earnings		 -89 -129 -174 -237 -297 -384 -539 -546 -617 -698 -891

Quarterly Balance Sheets for Ocular Therapeutix

This table presents Ocular Therapeutix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 159 129 123 162 539 517 490
Total Current Assets		 146 107 101 141 520 499 473
Cash & Equivalents		 121 79 67 111 483 460 427
Restricted Cash		 - - - - 0.15 0.00 0.00
Accounts Receivable		 20 21 27 24 27 30 30
Inventories, net		 1.55 2.27 2.20 2.26 2.57 2.55 2.41
Prepaid Expenses		 3.32 4.75 4.59 4.86 7.67 6.12 13
Plant, Property, & Equipment, net		 7.20 12 13 12 11 11 10
Total Noncurrent Assets		 5.77 9.39 9.02 8.63 7.67 7.62 7.31
Other Noncurrent Operating Assets		 4.00 7.63 7.25 6.87 7.67 7.62 7.31
Total Liabilities & Shareholders' Equity		 159 129 123 162 539 517 490
Total Liabilities		 112 119 119 155 131 139 138
Total Current Liabilities		 29 30 32 35 24 30 36
Accounts Payable		 5.31 5.44 3.57 3.98 6.45 3.69 4.00
Accrued Expenses		 22 22 25 29 16 24 30
Current Deferred Revenue		 0.60 0.46 0.39 0.32 0.26 0.27 0.19
Other Current Liabilities		 1.74 1.82 1.71 1.88 1.54 1.66 1.72
Total Noncurrent Liabilities		 83 89 87 119 107 109 102
Long-Term Debt		 53 55 53 74 66 67 68
Noncurrent Deferred Revenue		 14 13 14 14 14 14 14
Other Noncurrent Operating Liabilities		 16 21 20 31 26 28 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 46 9.71 3.09 7.85 408 378 352
Total Preferred & Common Equity		 46 9.71 3.09 7.85 408 378 352
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 46 9.71 3.09 7.85 408 378 352
Common Stock		 648 657 671 676 1,170 1,184 1,195
Retained Earnings		 -601 -647 -668 -668 -762 -806 -843

Annual Metrics and Ratios for Ocular Therapeutix

This table displays calculated financial ratios and metrics derived from Ocular Therapeutix's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 126.68% 7.83% 1.91% 3.48% 112.41% 311.71% 150.08% 18.32% 13.49% 9.03%
EBITDA Growth		 -115.95% -37.69% -13.25% -42.92% 5.73% -33.40% -88.41% 105.03% -910.92% -35.66% -109.91%
EBIT Growth		 -113.64% -38.69% -13.45% -42.91% 4.52% -37.86% -82.87% 100.06% -76,350.59% -35.11% -96.71%
NOPAT Growth		 -109.98% -40.98% -13.43% -42.92% 4.53% -45.14% 26.75% -24.17% -0.79% -4.74% -108.52%
Net Income Growth		 -115.12% -38.75% -12.47% -41.79% 5.38% -44.01% -80.19% 95.79% -984.05% -13.65% -139.68%
EPS Growth		 47.36% 36.43% -5.26% -22.22% 28.64% -21.66% -34.03% 61.72% 1.02% -5.15% -19.61%
Operating Cash Flow Growth		 -62.09% -64.63% -0.76% -48.45% 2.47% -57.59% 30.97% -22.40% 9.07% -17.84% -91.75%
Free Cash Flow Firm Growth		 -107.17% -55.53% -2.65% -63.22% 13.35% -22.79% 200.25% -366.35% 49.46% 36.53% -234.30%
Invested Capital Growth		 -270.05% 71.10% -414.35% 145.50% -101.29% -80,815.38% -890.52% 74.57% 44.60% -103.70% 72.40%
Revenue Q/Q Growth		 0.00% -3.79% 4.14% 27.44% -17.46% 70.79% 41.37% 12.86% 3.55% 1.26% 3.71%
EBITDA Q/Q Growth		 0.00% -6.39% -6.05% -0.24% -8.62% 1.77% -72.36% 109.57% -26.09% -17.39% -17.39%
EBIT Q/Q Growth		 0.00% -7.67% -5.34% -0.39% -8.37% 0.23% -66.39% 100.10% -22.58% -16.51% -15.74%
NOPAT Q/Q Growth		 0.00% -7.69% -5.34% -0.40% -8.37% -5.04% 10.10% -4.99% -1.70% -0.84% -21.61%
Net Income Q/Q Growth		 0.00% -7.24% -5.14% -0.44% -7.72% -11.08% -62.05% 92.58% -19.70% -20.40% -10.99%
EPS Q/Q Growth		 0.00% -259.81% -4.05% 3.08% 1.26% -1.06% -50.59% 51.49% 6.73% 6.42% -11.93%
Operating Cash Flow Q/Q Growth		 -11.84% -9.79% 2.92% -5.81% -7.10% -8.11% 19.80% -15.72% -3.12% -8.49% -14.42%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 1.90% -6.46% -4.97% -2.83% 270.42% -260.47% 9.49% 14.69% -16.24%
Invested Capital Q/Q Growth		 0.00% -726.09% -702.17% 6.87% -101.08% -35.22% -278.06% 38.22% 36.57% 2.19% -11.77%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.21% 81.77% 76.52% 76.24% 76.63% 45.00% 88.03% 89.88% 91.18% 90.96% 91.17%
EBITDA Margin		 -3,479.53% -2,113.54% -2,219.87% -3,113.26% -2,835.93% -1,781.10% -815.08% 16.39% -112.35% -134.29% -258.53%
Operating Margin		 -3,509.59% -2,182.69% -2,296.03% -3,220.12% -2,970.75% -2,029.86% -361.13% -179.30% -152.74% -140.96% -269.57%
EBIT Margin		 -3,566.84% -2,182.29% -2,296.08% -3,219.86% -2,970.75% -1,928.08% -856.38% 0.20% -125.87% -149.84% -270.33%
Profit (Net Income) Margin		 -3,710.88% -2,271.31% -2,369.00% -3,296.20% -3,013.97% -2,043.34% -894.31% -15.06% -137.95% -138.14% -303.67%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.04% 104.08% 103.18% 102.37% 101.45% 105.98% 104.43% -7,709.41% 109.60% 92.19% 112.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -8,293.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -8,232.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 8,099.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.88% -53.61% -63.14% -162.21% -193.41% -535.72% -429.55% -7.99% -115.16% -127.64% -95.21%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -4,607.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -56.58% -40.52% -46.78% -94.99% -92.03% -107.39% -87.51% 0.04% -36.60% -43.64% -48.52%
Return on Assets (ROA)		 -58.86% -42.17% -48.26% -97.24% -93.37% -113.81% -91.39% -2.81% -40.11% -40.23% -54.51%
Return on Common Equity (ROCE)		 0.82% -53.61% -63.14% -162.21% -193.41% -535.72% -429.55% -7.99% -115.16% -127.64% -95.21%
Return on Equity Simple (ROE_SIMPLE)		 -48.81% -44.37% -85.95% -242.42% -167.19% 2,379.39% -204.53% -7.45% -200.79% -88.59% -61.36%
Net Operating Profit after Tax (NOPAT)		 -19 -27 -30 -43 -41 -60 -44 -55 -55 -58 -120
NOPAT Margin		 -2,456.71% -1,527.88% -1,607.22% -2,254.09% -2,079.53% -1,420.90% -252.79% -125.51% -106.92% -98.67% -188.70%
Net Nonoperating Expense Percent (NNEP)		 -25.66% -17.32% -19.93% -50.50% -60.94% -123.01% -119.29% 32.62% -19.42% -26.97% -32.95%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -61.60% -34.73% -31.33%
Cost of Revenue to Revenue		 11.79% 18.23% 23.48% 23.77% 23.37% 55.00% 11.97% 10.12% 8.82% 9.04% 8.83%
SG&A Expenses to Revenue		 895.47% 523.71% 583.15% 806.50% 944.02% 523.35% 131.35% 73.25% 62.58% 58.07% 95.18%
R&D to Revenue		 2,445.60% 1,520.63% 1,434.29% 1,605.82% 1,855.03% 972.11% 164.88% 115.08% 103.82% 104.47% 200.30%
Operating Expenses to Revenue		 3,597.80% 2,264.46% 2,372.55% 3,296.36% 3,047.39% 2,074.85% 449.16% 269.18% 243.93% 231.93% 360.75%
Earnings before Interest and Taxes (EBIT)		 -28 -38 -43 -62 -59 -82 -149 0.09 -65 -88 -172
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -37 -42 -60 -56 -75 -142 7.13 -58 -78 -165
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.54 2.59 4.00 5.01 4.56 0.00 19.42 6.07 6.12 3.89 4.26
Price to Tangible Book Value (P/TBV)		 8.54 2.59 4.00 5.01 4.56 0.00 19.42 6.07 6.12 3.89 4.26
Price to Revenue (P/Rev)		 649.62 132.43 110.36 68.12 82.19 44.93 84.92 12.27 4.20 6.06 21.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 106.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 571.94 81.12 82.53 55.89 67.48 43.72 74.66 9.68 3.26 3.99 15.99
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 59.05 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,955.81 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 26.15 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.25 0.17 0.30 0.69 0.69 -13.58 0.65 0.58 1.53 0.82 0.22
Long-Term Debt to Equity		 0.23 0.17 0.27 0.48 0.69 -13.58 0.54 0.58 1.53 0.82 0.22
Financial Leverage		 -1.03 -1.01 -1.02 -1.02 -0.98 -1.33 -2.58 -1.80 -1.33 -1.35 -1.09
Leverage Ratio		 1.32 1.27 1.31 1.67 2.07 4.71 4.70 2.84 2.87 3.17 1.75
Compound Leverage Factor		 1.38 1.32 1.35 1.71 2.10 4.99 4.91 -219.29 3.15 2.92 1.96
Debt to Total Capital		 20.21% 14.56% 23.12% 40.79% 40.86% 107.95% 39.43% 36.89% 60.42% 45.12% 17.85%
Short-Term Debt to Total Capital		 1.84% 0.00% 2.29% 12.56% 0.00% 0.00% 6.60% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 18.37% 14.56% 20.83% 28.24% 40.86% 107.95% 32.83% 36.89% 60.42% 45.12% 17.85%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 79.79% 85.44% 76.88% 59.21% 59.14% -7.95% 60.57% 63.11% 39.58% 54.88% 82.15%
Debt to EBITDA		 -0.55 -0.41 -0.37 -0.30 -0.44 -0.66 -0.35 7.21 -0.93 -0.95 -0.42
Net Debt to EBITDA		 2.23 2.43 1.25 0.39 0.52 0.07 1.26 -15.80 0.83 1.54 1.96
Long-Term Debt to EBITDA		 -0.50 -0.41 -0.34 -0.21 -0.44 -0.66 -0.29 7.21 -0.93 -0.95 -0.42
Debt to NOPAT		 -0.78 -0.57 -0.52 -0.42 -0.60 -0.82 -1.13 -0.94 -0.98 -1.30 -0.57
Net Debt to NOPAT		 3.16 3.36 1.73 0.54 0.71 0.09 4.06 2.06 0.88 2.10 2.69
Long-Term Debt to NOPAT		 -0.71 -0.57 -0.46 -0.29 -0.60 -0.82 -0.94 -0.94 -0.98 -1.30 -0.57
Altman Z-Score		 13.76 5.05 1.30 -6.31 -4.93 -8.07 1.08 0.19 -4.94 -2.53 2.87
Noncontrolling Interest Sharing Ratio		 101.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.97 19.89 8.42 3.23 6.14 5.00 9.23 7.26 4.13 6.66 10.66
Quick Ratio		 12.79 19.57 8.24 3.11 5.92 4.74 9.01 7.04 3.94 6.36 10.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -28 -29 -47 -40 -50 50 -132 -67 -42 -142
Operating Cash Flow to CapEx		 -1,626.67% -1,905.31% -1,773.66% -612.02% -2,605.98% -3,466.40% -6,367.90% -5,489.95% -1,604.39% -1,153.84% -10,456.29%
Free Cash Flow to Firm to Interest Expense		 -15.97 -16.13 -16.99 -24.62 -23.21 -8.12 7.34 -19.84 -9.52 0.00 -3.42
Operating Cash Flow to Interest Expense		 -18.32 -19.57 -20.24 -26.68 -28.31 -12.72 -7.91 -9.83 -8.49 0.00 -3.24
Operating Cash Flow Less CapEx to Interest Expense		 -19.44 -20.60 -21.38 -31.04 -29.39 -13.08 -8.04 -10.01 -9.02 0.00 -3.27
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.02 0.03 0.03 0.06 0.10 0.19 0.29 0.29 0.18
Accounts Receivable Turnover		 2.58 6.71 8.52 8.08 9.32 3.08 2.35 2.61 2.43 2.46 2.18
Inventory Turnover		 0.00 2.39 3.59 3.89 2.74 3.97 1.93 3.60 2.82 2.47 2.11
Fixed Asset Turnover		 0.57 0.72 0.59 0.28 0.19 0.41 1.91 5.78 6.13 5.41 6.03
Accounts Payable Turnover		 0.10 0.19 0.22 0.16 0.14 0.75 0.70 1.21 0.93 1.11 1.31
Days Sales Outstanding (DSO)		 141.37 54.44 42.84 45.17 39.16 118.69 155.20 140.00 150.48 148.34 167.73
Days Inventory Outstanding (DIO)		 0.00 152.75 101.76 93.85 133.05 91.92 188.81 101.52 129.60 147.87 173.38
Days Payable Outstanding (DPO)		 3,732.23 1,872.48 1,677.93 2,271.07 2,565.20 489.26 523.67 302.41 390.53 328.71 277.84
Cash Conversion Cycle (CCC)		 -3,590.86 -1,665.30 -1,533.33 -2,132.05 -2,393.00 -278.65 -179.66 -60.89 -110.44 -32.50 63.28
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.50 -0.43 -2.22 1.01 -0.01 -11 -104 -26 -15 -30 -8.25
Invested Capital Turnover		 -0.81 -1.82 -1.42 -3.18 3.99 -0.80 -0.30 -0.67 -2.50 -2.62 -3.34
Increase / (Decrease) in Invested Capital		 -1.09 1.06 -1.79 3.23 -1.02 -11 -94 78 12 -15 22
Enterprise Value (EV)		 442 142 156 107 134 185 1,299 421 168 233 1,019
Market Capitalization		 502 232 208 131 164 190 1,478 534 216 354 1,343
Book Value per Share		 $2.75 $3.62 $2.09 $0.89 $0.87 ($0.08) $1.07 $1.15 $0.46 $1.15 $2.01
Tangible Book Value per Share		 $2.75 $3.62 $2.09 $0.89 $0.87 ($0.08) $1.07 $1.15 $0.46 $1.15 $2.01
Total Capital		 74 105 68 44 61 46 126 139 89 166 384
Total Debt		 15 15 16 18 25 49 50 51 54 75 69
Total Long-Term Debt		 14 15 14 12 25 49 41 51 54 75 69
Net Debt		 -60 -90 -53 -24 -29 -5.13 -179 -113 -48 -121 -324
Capital Expenditures (CapEx)		 1.26 1.77 1.92 8.25 1.89 2.24 0.84 1.19 3.72 6.09 1.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.17 -3.46 -5.00 -6.08 -7.03 -6.30 -0.27 0.80 -4.07 1.38 7.53
Debt-free Net Working Capital (DFNWC)		 72 102 63 35 47 48 228 165 98 197 400
Net Working Capital (NWC)		 70 102 62 30 47 48 219 165 98 197 400
Net Nonoperating Expense (NNE)		 9.68 13 14 20 19 26 112 -48 16 23 73
Net Nonoperating Obligations (NNO)		 -60 -90 -54 -25 -36 -6.89 -180 -114 -50 -121 -324
Total Depreciation and Amortization (D&A)		 0.67 1.20 1.44 2.05 2.68 6.21 7.19 7.05 6.96 9.09 7.52
Debt-free, Cash-free Net Working Capital to Revenue		 -409.97% -197.66% -264.86% -316.17% -353.17% -148.95% -1.56% 1.84% -7.90% 2.36% 11.82%
Debt-free Net Working Capital to Revenue		 9,282.77% 5,806.00% 3,346.42% 1,843.89% 2,363.52% 1,138.89% 1,308.89% 379.03% 190.76% 337.66% 627.14%
Net Working Capital to Revenue		 9,107.38% 5,806.00% 3,264.33% 1,555.54% 2,363.52% 1,138.89% 1,261.25% 379.03% 190.76% 337.66% 627.14%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.69) ($1.71) ($1.80) ($2.20) ($1.57) ($1.91) ($2.56) ($0.09) ($0.92) ($1.01) ($1.22)
Adjusted Weighted Average Basic Shares Outstanding		 21.42M 24.75M 28.76M 37.28M 42.84M 52.58M 76.07M 76.39M 76.88M 79.83M 158.27M
Adjusted Diluted Earnings per Share		 ($2.69) ($1.71) ($1.80) ($2.20) ($1.57) ($1.91) ($2.56) ($0.98) ($0.97) ($1.02) ($1.22)
Adjusted Weighted Average Diluted Shares Outstanding		 21.42M 24.75M 28.76M 37.28M 42.84M 52.58M 76.07M 82.16M 82.64M 85.60M 158.27M
Adjusted Basic & Diluted Earnings per Share		 ($2.69) ($1.71) ($1.80) ($2.20) ($1.57) ($1.91) ($2.56) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.65M 23.24M 24.82M 28.82M 38.12M 45.27M 60.75M 76.75M 77.51M 148.63M 159.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -27 -30 -43 -41 -60 -44 -55 -55 -58 -120
Normalized NOPAT Margin		 -2,456.71% -1,527.88% -1,607.22% -2,254.09% -2,079.53% -1,420.90% -252.79% -125.51% -106.92% -98.67% -188.70%
Pre Tax Income Margin		 -3,710.88% -2,271.31% -2,369.00% -3,296.20% -3,013.97% -2,043.34% -894.31% -15.06% -137.95% -138.14% -303.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -24.61 -22.15 -25.79 -32.73 -34.00 -13.36 -22.02 0.01 -9.23 0.00 -4.15
NOPAT to Interest Expense		 -16.95 -15.51 -18.05 -22.91 -23.80 -9.84 -6.50 -8.19 -7.84 0.00 -2.90
EBIT Less CapEx to Interest Expense		 -25.73 -23.18 -26.93 -37.09 -35.08 -13.73 -22.14 -0.17 -9.76 0.00 -4.18
NOPAT Less CapEx to Interest Expense		 -18.07 -16.54 -19.19 -27.27 -24.88 -10.21 -6.62 -8.37 -8.37 0.00 -2.93
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -10.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.20% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Ocular Therapeutix

This table displays calculated financial ratios and metrics derived from Ocular Therapeutix's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -1.55% 14.36% 1.42% 23.81% 26.04% 5.16% 10.47% 8.26% 2.28% 15.41%
EBITDA Growth		 -445.58% -2,856.80% -200.00% -13.96% 54.49% -93.84% -23.64% -157.17% -291.84% -101.65%
EBIT Growth		 -626.37% -548.46% -167.66% -13.39% 44.91% -87.90% -26.30% -139.81% -211.58% -88.32%
NOPAT Growth		 22.78% -7.27% -26.45% -3.28% 10.82% -3.55% -40.21% -111.91% -139.40% -152.26%
Net Income Growth		 -1,010.35% -303.69% -141.73% -10.21% 97.87% -88.01% -113.89% -111.67% -6,972.29% -65.60%
EPS Growth		 -34.78% 26.92% -77.27% -4.00% 19.35% 36.84% -25.64% 0.00% 12.00% -108.33%
Operating Cash Flow Growth		 -1.44% -11.91% -7.38% -84.58% 41.29% -32.41% -69.66% -23.55% -372.83% -75.60%
Free Cash Flow Firm Growth		 -727.93% 71.92% 80.86% 62.40% 82.72% 104.68% -103.45% -14.71% -820.23% -4,903.50%
Invested Capital Growth		 46.04% 44.60% -6.99% 44.31% -32.11% -103.70% 47.57% -49.89% 75.85% 72.40%
Revenue Q/Q Growth		 -2.45% 17.64% -4.99% 13.55% -0.69% -1.85% -0.19% 11.28% -6.18% 10.75%
EBITDA Q/Q Growth		 -36.11% 40.84% -121.16% 36.01% 45.65% -151.99% -41.08% -33.09% 17.19% -29.68%
EBIT Q/Q Growth		 -32.28% 37.74% -106.21% 33.23% 35.74% -112.34% -38.61% -26.78% 16.51% -28.34%
NOPAT Q/Q Growth		 -8.17% 10.13% -16.47% 8.78% 6.59% -4.35% -57.70% -37.87% -5.52% -9.95%
Net Income Q/Q Growth		 -28.89% 35.75% -95.07% 31.78% 97.51% -5,562.79% -121.93% 32.49% 16.64% -32.60%
EPS Q/Q Growth		 -24.00% 38.71% -105.26% 33.33% 3.85% 52.00% -308.33% 46.94% 15.38% -13.64%
Operating Cash Flow Q/Q Growth		 -21.08% -28.77% -17.78% -0.51% 61.48% -190.40% -50.92% 26.81% -47.40% -7.85%
Free Cash Flow Firm Q/Q Growth		 41.25% 27.15% 42.00% -51.49% 73.00% 119.73% -2,620.24% 14.59% -116.64% -3.01%
Invested Capital Q/Q Growth		 -29.97% 36.57% -11.72% 39.54% -208.31% 2.19% 71.24% -72.85% 50.32% -11.77%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 91.03% 92.81% 90.92% 91.41% 90.87% 90.64% 91.02% 90.82% 89.88% 92.80%
EBITDA Margin		 -175.03% -88.02% -204.89% -115.46% -63.19% -162.24% -229.33% -274.27% -242.09% -283.47%
Operating Margin		 -180.06% -137.55% -168.60% -135.45% -127.41% -135.45% -214.00% -265.13% -298.20% -296.06%
EBIT Margin		 -189.52% -100.29% -217.68% -128.01% -82.83% -179.21% -248.88% -283.54% -252.33% -292.41%
Profit (Net Income) Margin		 -202.16% -110.41% -226.69% -136.19% -3.42% -197.41% -438.93% -266.27% -236.58% -283.25%
Tax Burden Percent		 100.00% 100.01% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 106.67% 110.09% 104.14% 106.39% 4.13% 110.15% 176.37% 93.91% 93.76% 96.87%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -88.86% -115.16% -198.45% -263.41% -247.99% -127.64% -55.19% -72.67% -96.89% -95.21%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -50.09% -29.16% -71.16% -47.28% -29.79% -52.19% -44.62% -54.17% -47.50% -52.49%
Return on Assets (ROA)		 -53.43% -32.11% -74.10% -50.31% -1.23% -57.49% -78.70% -50.87% -44.54% -50.84%
Return on Common Equity (ROCE)		 -88.86% -115.16% -198.45% -263.41% -247.99% -127.64% -55.19% -72.67% -96.89% -95.21%
Return on Equity Simple (ROE_SIMPLE)		 -128.37% 0.00% -914.57% -2,939.10% -853.92% 0.00% -28.25% -36.63% -49.52% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -14 -16 -14 -13 -14 -22 -31 -32 -35
NOPAT Margin		 -126.04% -96.28% -118.02% -94.82% -89.18% -94.81% -149.80% -185.59% -208.74% -207.24%
Net Nonoperating Expense Percent (NNEP)		 -9.13% -2.42% -23.98% -13.01% 24.00% -17.75% -19.30% -6.54% -2.16% -5.84%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.16% - - - -8.45% - - - -9.22%
Cost of Revenue to Revenue		 8.97% 7.19% 9.08% 8.59% 9.13% 9.36% 8.98% 9.18% 10.12% 7.20%
SG&A Expenses to Revenue		 71.30% 59.31% 68.24% 54.03% 56.92% 54.21% 95.76% 119.65% 79.32% 85.47%
R&D to Revenue		 114.66% 96.21% 110.27% 99.39% 99.59% 109.41% 140.35% 175.52% 240.22% 239.94%
Operating Expenses to Revenue		 271.09% 230.36% 259.53% 226.87% 218.27% 226.08% 305.03% 355.95% 388.08% 388.86%
Earnings before Interest and Taxes (EBIT)		 -23 -14 -29 -19 -12 -27 -37 -47 -39 -50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -12 -27 -18 -9.53 -24 -34 -45 -37 -48
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 6.91 6.12 42.06 129.58 31.74 3.89 3.32 2.81 3.85 4.26
Price to Tangible Book Value (P/TBV)		 6.91 6.12 42.06 129.58 31.74 3.89 3.32 2.81 3.85 4.26
Price to Revenue (P/Rev)		 6.42 4.20 7.90 7.33 4.32 6.06 22.60 17.34 22.08 21.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.06 3.26 7.43 7.12 3.68 3.99 15.64 10.92 16.23 15.99
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.15 1.53 5.63 17.94 9.41 0.82 0.16 0.18 0.19 0.22
Long-Term Debt to Equity		 1.15 1.53 5.63 17.26 9.41 0.82 0.16 0.18 0.19 0.22
Financial Leverage		 -1.49 -1.33 -1.35 -1.40 -1.99 -1.35 -1.06 -1.07 -1.11 -1.09
Leverage Ratio		 2.82 2.87 3.53 4.29 5.93 3.17 1.60 1.68 1.81 1.75
Compound Leverage Factor		 3.01 3.16 3.68 4.57 0.25 3.49 2.82 1.58 1.70 1.69
Debt to Total Capital		 53.57% 60.42% 84.92% 94.72% 90.39% 45.12% 14.01% 15.09% 16.15% 17.85%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 3.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 53.57% 60.42% 84.92% 91.16% 90.39% 45.12% 14.01% 15.09% 16.15% 17.85%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 46.43% 39.58% 15.08% 5.28% 9.61% 54.88% 85.99% 84.91% 83.85% 82.15%
Debt to EBITDA		 -1.16 -0.93 -0.72 -0.71 -1.11 -0.95 -0.78 -0.60 -0.48 -0.42
Net Debt to EBITDA		 1.47 0.83 0.32 0.14 0.55 1.54 4.90 3.49 2.56 1.96
Long-Term Debt to EBITDA		 -1.16 -0.93 -0.72 -0.68 -1.11 -0.95 -0.78 -0.60 -0.48 -0.42
Debt to NOPAT		 -0.99 -0.98 -0.94 -0.94 -1.29 -1.30 -1.04 -0.84 -0.69 -0.57
Net Debt to NOPAT		 1.25 0.88 0.42 0.19 0.64 2.10 6.51 4.90 3.63 2.69
Long-Term Debt to NOPAT		 -0.99 -0.98 -0.94 -0.91 -1.29 -1.30 -1.04 -0.84 -0.69 -0.57
Altman Z-Score		 -2.88 -3.82 -4.61 -5.03 -3.91 -1.73 5.21 3.29 4.41 3.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 4.98 4.13 3.61 3.11 4.03 6.66 21.39 16.64 13.01 10.66
Quick Ratio		 4.81 3.94 3.37 2.90 3.83 6.36 20.97 16.35 12.58 10.26
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -35 -25 -15 -22 -6.02 1.19 -30 -26 -55 -57
Operating Cash Flow to CapEx		 -1,658.56% -788.74% -591.09% -1,008.79% -2,985.33% -4,891.94% -13,289.02% -3,342.59% -41,077.53% -19,519.31%
Free Cash Flow to Firm to Interest Expense		 -19.38 -13.74 -8.32 -11.19 0.00 0.29 -0.94 -8.00 -17.18 -18.37
Operating Cash Flow to Interest Expense		 -7.33 -9.19 -11.30 -10.08 0.00 -5.41 -1.06 -7.76 -11.34 -12.69
Operating Cash Flow Less CapEx to Interest Expense		 -7.77 -10.35 -13.21 -11.08 0.00 -5.52 -1.07 -7.99 -11.37 -12.76
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.26 0.29 0.33 0.37 0.36 0.29 0.18 0.19 0.19 0.18
Accounts Receivable Turnover		 2.53 2.43 2.33 2.29 2.66 2.46 2.51 2.12 2.28 2.18
Inventory Turnover		 3.35 2.82 2.46 2.49 2.58 2.47 2.23 2.36 2.48 2.11
Fixed Asset Turnover		 7.05 6.13 5.55 5.60 5.86 5.41 5.10 5.15 5.45 6.03
Accounts Payable Turnover		 0.97 0.93 1.01 1.27 1.06 1.11 0.91 1.54 1.45 1.31
Days Sales Outstanding (DSO)		 144.43 150.48 156.55 159.74 137.20 148.34 145.38 171.88 159.87 167.73
Days Inventory Outstanding (DIO)		 108.93 129.60 148.49 146.86 141.40 147.87 163.79 154.89 147.15 173.38
Days Payable Outstanding (DPO)		 376.10 390.53 363.07 288.44 345.59 328.71 402.49 236.72 252.03 277.84
Cash Conversion Cycle (CCC)		 -122.75 -110.44 -58.04 18.15 -66.98 -32.50 -93.33 90.05 54.99 63.28
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -23 -15 -16 -9.92 -31 -30 -8.60 -15 -7.38 -8.25
Invested Capital Turnover		 -1.51 -2.50 -3.26 -3.94 -2.15 -2.62 -4.79 -4.93 -3.24 -3.34
Increase / (Decrease) in Invested Capital		 20 12 -1.07 7.89 -7.43 -15 7.80 -4.95 23 22
Enterprise Value (EV)		 252 168 384 389 213 233 936 667 997 1,019
Market Capitalization		 319 216 408 400 249 354 1,353 1,059 1,357 1,343
Book Value per Share		 $0.60 $0.46 $0.13 $0.04 $0.10 $1.15 $2.75 $2.44 $2.26 $2.01
Tangible Book Value per Share		 $0.60 $0.46 $0.13 $0.04 $0.10 $1.15 $2.75 $2.44 $2.26 $2.01
Total Capital		 100 89 64 58 82 166 474 445 420 384
Total Debt		 53 54 55 55 74 75 66 67 68 69
Total Long-Term Debt		 53 54 55 53 74 75 66 67 68 69
Net Debt		 -68 -48 -24 -11 -37 -121 -417 -393 -359 -324
Capital Expenditures (CapEx)		 0.79 2.15 3.38 1.99 0.26 0.46 0.26 0.74 0.09 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.60 -4.07 -1.58 3.83 -4.36 1.38 12 8.92 9.43 7.53
Debt-free Net Working Capital (DFNWC)		 116 98 77 70 106 197 496 469 437 400
Net Working Capital (NWC)		 116 98 77 68 106 197 496 469 437 400
Net Nonoperating Expense (NNE)		 9.11 1.99 15 6.28 -13 15 43 13 4.29 13
Net Nonoperating Obligations (NNO)		 -69 -50 -26 -13 -38 -121 -417 -393 -359 -324
Total Depreciation and Amortization (D&A)		 1.73 1.73 1.71 1.91 2.96 2.51 2.89 1.53 1.58 1.53
Debt-free, Cash-free Net Working Capital to Revenue		 -9.26% -7.90% -3.06% 7.02% -7.55% 2.36% 20.87% 14.60% 15.35% 11.82%
Debt-free Net Working Capital to Revenue		 233.97% 190.76% 149.86% 129.01% 183.99% 337.66% 828.04% 766.99% 710.67% 627.14%
Net Working Capital to Revenue		 233.97% 190.76% 149.86% 125.19% 183.99% 337.66% 828.04% 766.99% 710.67% 627.14%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.31) ($0.21) ($0.39) ($0.26) ($0.01) ($0.35) ($0.49) ($0.26) ($0.22) ($0.25)
Adjusted Weighted Average Basic Shares Outstanding		 76.98M 76.88M 77.39M 78.05M 79.37M 79.83M 132.02M 165.82M 166.99M 158.27M
Adjusted Diluted Earnings per Share		 ($0.31) ($0.19) ($0.39) ($0.26) ($0.25) ($0.12) ($0.49) ($0.26) ($0.22) ($0.25)
Adjusted Weighted Average Diluted Shares Outstanding		 76.98M 82.64M 77.39M 78.05M 85.14M 85.60M 132.02M 165.82M 166.99M 158.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 77.01M 77.51M 77.52M 79.38M 79.42M 148.63M 154.89M 155.92M 157.22M 159.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -14 -16 -14 -13 -14 -22 -31 -32 -35
Normalized NOPAT Margin		 -126.04% -96.28% -118.02% -94.82% -89.18% -94.81% -149.80% -185.59% -208.74% -207.24%
Pre Tax Income Margin		 -202.16% -110.41% -226.69% -136.19% -3.42% -197.40% -438.93% -266.27% -236.58% -283.25%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -12.62 -7.65 -16.47 -9.76 0.00 -6.39 -1.15 -14.59 -12.07 -16.08
NOPAT to Interest Expense		 -8.39 -7.34 -8.93 -7.23 0.00 -3.38 -0.69 -9.55 -9.99 -11.40
EBIT Less CapEx to Interest Expense		 -13.06 -8.81 -18.38 -10.76 0.00 -6.50 -1.16 -14.82 -12.10 -16.15
NOPAT Less CapEx to Interest Expense		 -8.83 -8.51 -10.84 -8.23 0.00 -3.49 -0.70 -9.78 -10.01 -11.46
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Ocular Therapeutix's Financials

When does Ocular Therapeutix's financial year end?

According to the most recent income statement we have on file, Ocular Therapeutix's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Ocular Therapeutix's net income changed over the last 10 years?

Ocular Therapeutix's net income appears to be on an upward trend, with a most recent value of -$193.51 million in 2024, rising from -$28.65 million in 2014. The previous period was -$80.74 million in 2023.

What is Ocular Therapeutix's operating income?
Ocular Therapeutix's total operating income in 2024 was -$171.78 million, based on the following breakdown:
  • Total Gross Profit: $58.10 million
  • Total Operating Expenses: $229.88 million
How has Ocular Therapeutix revenue changed over the last 10 years?

Over the last 10 years, Ocular Therapeutix's total revenue changed from $772 thousand in 2014 to $63.72 million in 2024, a change of 8,154.3%.

How much debt does Ocular Therapeutix have?

Ocular Therapeutix's total liabilities were at $142.59 million at the end of 2024, a 11.4% decrease from 2023, and a 631.3% increase since 2014.

How much cash does Ocular Therapeutix have?

In the past 10 years, Ocular Therapeutix's cash and equivalents has ranged from $30.78 million in 2015 to $392.10 million in 2024, and is currently $392.10 million as of their latest financial filing in 2024.

How has Ocular Therapeutix's book value per share changed over the last 10 years?

Over the last 10 years, Ocular Therapeutix's book value per share changed from 2.75 in 2014 to 2.01 in 2024, a change of -27.1%.


Related Companies

This page (NASDAQ:OCUL) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Trump purposefully forcing markets to crash…
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...
Porter & Company | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
Amazon Shocker
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...
Stansberry Research | Sponsored